Cardiac muscle-related microRNAs play important roles in cardiac development and disease by translational silencing of mRNAs, the dominant mechanism of microRNA action. To test whether they could be involved in daunorubicin-associated cardiomyopathy (DACM), we determined expression patterns of myomiRs in two distinct models of DACM. We used 10-12 weeks old male Wistar rats. In the sub-acute model, rats were administered with six doses of daunorubicin (DAU-A, 3 mg/kg, i.p., every 48 h). Rats were sacrificed two days after the last dose. In the sub-chronic model, anaesthetized rats were administered a single dose of daunorubicin (15 mg/kg, i.v., DAU-C). Age-matched controls (CON) received vehicle. Rats were sacrificed eight weeks later. Left ventricular (LV) functions (LV pressure, rate of pressure development, +dP/dt and decline, -dP/dt) were measured using left ventricular catheterization. Expressions of myomiRs (miR-208a, miR-499, miR-1 and miR-133a), markers of cardiac failure (atrial and brain natriuretic peptides genes; Nppa and Nppb) and myosin heavy chain genes (Myh6, Myh7, Myh7b) in cardiac tissue were determined by RT-PCR. Protein expression of gp91phox NADPH oxidase subunit was detected by immunoblotting. Both DAU groups exhibited a similar depression of LV function, and LV weight reduction, accompanied by an upregulation of natriuretic peptides, and a decrease of Myh6 to total Myh ratio (-18% in DAU-A and - 25% in DAU-C, as compared to controls; both P < 0.05). DAU-C, but not DAU-A rats had a 35% mortality rate and exhibited a significantly increased gp91phox expression (DAU-C: 197 ± 33 versus CON-C: 100 ± 11; P < 0.05). Interestingly, myomiRs levels were only reduced in DAU-C compared to CON-C (miR-208: -45%, miR-499: -30%, miR-1: -29%, miR- and miR133a: -25%; all P < 0.05) but were unaltered in DAU-A. The lack of myomiRs expression, particularly in sub-chronic model, suggests the loss of control of myomiRs network on late progression of DACM. We suppose that the poor inhibition of mRNA targets might contribute to chronic DACM.

Central University Hospital of Asturias University of Oviedo Oviedo Spain

Department of Chemical Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Czech Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy Comenius University Bratislava Slovakia

Department of Thoracic Surgery Faculty of Medicine and Dentistry Medical University of Silesia Katowice Poland

Human Anatomy Section Department of Experimental Biomedicine and Clinical Neurosciences University of Palermo and Euro Mediterranean Institute of Science and Technology Palermo Italy

Zobrazit více v PubMed

Nucleic Acids Res. 2012 Aug;40(15):7303-18 PubMed

Cancer Res. 2010 Nov 15;70(22):9287-97 PubMed

Eur J Pharmacol. 2010 Sep 1;641(2-3):187-92 PubMed

Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H1048-57 PubMed

Circulation. 2011 Oct 4;124(14 ):1537-47 PubMed

J Pharmacol Exp Ther. 2011 Dec;339(3):807-14 PubMed

Cell Death Dis. 2015 May 07;6:e1754 PubMed

PLoS One. 2011 May 09;6(5):e19481 PubMed

Circulation. 2006 Jan 31;113(4):535-43 PubMed

Am J Pathol. 1984 Oct;117(1):140-53 PubMed

J Clin Invest. 2013 Jul;123(7):2921-34 PubMed

Med Sci Sports Exerc. 2008 May;40(5):808-17 PubMed

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11151-6 PubMed

Nat Med. 2011 Jan;17(1):71-8 PubMed

Circ Res. 2008 Oct 24;103(9):919-28 PubMed

Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H844-59 PubMed

Am J Pathol. 2007 Jun;170(6):1831-40 PubMed

PLoS One. 2014 May 07;9(5):e96055 PubMed

Circ Heart Fail. 2015 Jan;8(1):98-108 PubMed

Circ Res. 2009 Jan 30;104(2):170-8, 6p following 178 PubMed

J Clin Invest. 2009 Sep;119(9):2772-86 PubMed

Mol Cell Biochem. 2015 Jun;404(1-2):45-51 PubMed

Antioxid Redox Signal. 2013 Mar 10;18(8):899-929 PubMed

Clin Sci (Lond). 2008 Jun;114(12):699-706 PubMed

J Mol Cell Cardiol. 2007 Oct;43(4):388-403 PubMed

Clin Exp Pharmacol Physiol. 2014 Sep;41(9):727-37 PubMed

J Cell Sci. 2007 Sep 1;120(Pt 17):3045-52 PubMed

Cardiovasc Res. 2008 Sep 1;79(4):562-70 PubMed

Mol Pharmacol. 2000 Jun;57(6):1152-7 PubMed

Dev Cell. 2009 Nov;17(5):662-73 PubMed

Toxicology. 2006 Mar 15;220(2-3):160-8 PubMed

Toxicol Appl Pharmacol. 2015 Apr 15;284(2):152-62 PubMed

Pharmacol Rev. 2004 Jun;56(2):185-229 PubMed

Toxicol Appl Pharmacol. 2014 Dec 1;281(2):221-9 PubMed

J Biol Chem. 2003 May 9;278(19):17466-74 PubMed

Basic Clin Pharmacol Toxicol. 2015 Oct;117(4):251-60 PubMed

Dev Cell. 2010 Apr 20;18(4):510-25 PubMed

Circ Res. 2007 Feb 16;100(3):416-24 PubMed

Science. 2007 Apr 27;316(5824):575-9 PubMed

Circ Res. 2007 Dec 7;101(12):1225-36 PubMed

Nature. 2005 Jul 14;436(7048):214-20 PubMed

Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H37-46 PubMed

PLoS One. 2012;7(7):e40395 PubMed

Cardiovasc Toxicol. 2001;1(4):267-83 PubMed

Am J Transl Res. 2015 Jul 15;7(7):1280-94 PubMed

J Cardiol. 2013 Aug;62(2):110-6 PubMed

Am J Pathol. 2010 Feb;176(2):687-98 PubMed

Pharmacol Rep. 2009 Jan-Feb;61(1):154-71 PubMed

Nat Med. 2007 May;13(5):613-8 PubMed

Mol Cell Biol. 2009 Apr;29(8):2193-204 PubMed

Toxicology. 1996 Nov 15;114(1):1-10 PubMed

Circ Cardiovasc Genet. 2010 Oct;3(5):426-35 PubMed

Nucleic Acids Res. 2009 Apr;37(6):e45 PubMed